Trade Kaleido Biosciences, Inc. - KLDO CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.024068% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.001846% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 20% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
| Prev. Close* | 0.39 |
| Open* | 0.4 |
| 1-Year Change* | 2.56% |
| Day's Range* | 0.38 - 0.45 |
| 52 wk Range | 0.00-1.92 |
| Average Volume (10 days) | 26.79K |
| Average Volume (3 months) | 306.37K |
| Market Cap | 8,520.00 |
| P/E Ratio | -100.00K |
| Shares Outstanding | 42.62M |
| Revenue | 1.10M |
| EPS | -2.16 |
| Dividend (Yield %) | N/A |
| Beta | 0.47 |
| Next Earnings Date | Mar 23, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 14, 2022 | 0.38 | 0.00 | 0.00% | 0.38 | 0.38 | 0.38 |
| Apr 13, 2022 | 0.39 | 0.00 | 0.00% | 0.39 | 0.47 | 0.38 |
| Apr 8, 2022 | 0.40 | -0.24 | -37.50% | 0.64 | 0.64 | 0.38 |
| Apr 7, 2022 | 1.46 | -0.01 | -0.68% | 1.47 | 1.55 | 1.42 |
| Apr 6, 2022 | 1.46 | -0.02 | -1.35% | 1.48 | 1.48 | 1.42 |
| Apr 5, 2022 | 1.50 | -0.09 | -5.66% | 1.59 | 1.62 | 1.48 |
| Apr 4, 2022 | 1.59 | -0.14 | -8.09% | 1.73 | 1.73 | 1.54 |
| Apr 1, 2022 | 1.68 | 0.06 | 3.70% | 1.62 | 1.70 | 1.58 |
| Mar 31, 2022 | 1.60 | -0.08 | -4.76% | 1.68 | 1.72 | 1.55 |
| Mar 30, 2022 | 1.69 | -0.14 | -7.65% | 1.83 | 1.83 | 1.69 |
| Mar 29, 2022 | 1.70 | 0.02 | 1.19% | 1.68 | 1.77 | 1.60 |
| Mar 28, 2022 | 1.60 | -0.13 | -7.51% | 1.73 | 1.73 | 1.50 |
| Mar 25, 2022 | 1.64 | -0.10 | -5.75% | 1.74 | 1.74 | 1.63 |
| Mar 24, 2022 | 1.74 | 0.00 | 0.00% | 1.74 | 1.76 | 1.68 |
| Mar 23, 2022 | 1.74 | 0.01 | 0.58% | 1.73 | 1.81 | 1.73 |
| Mar 22, 2022 | 1.75 | 0.10 | 6.06% | 1.65 | 1.75 | 1.65 |
| Mar 21, 2022 | 1.63 | -0.05 | -2.98% | 1.68 | 1.68 | 1.55 |
| Mar 18, 2022 | 1.67 | 0.14 | 9.15% | 1.53 | 1.71 | 1.53 |
| Mar 17, 2022 | 1.56 | 0.14 | 9.86% | 1.42 | 1.57 | 1.42 |
| Mar 16, 2022 | 1.42 | 0.04 | 2.90% | 1.38 | 1.42 | 1.31 |
Kaleido Biosciences, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Annual
- Quarterly
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Total revenue | 1.104 | 0.975 | 0 | 0 | 0 |
| Total Operating Expense | 88.771 | 79.849 | 87.24 | 60.683 | 27.03 |
| Selling/General/Admin. Expenses, Total | 20.968 | 23.882 | 22.428 | 18.621 | 6.038 |
| Research & Development | 67.803 | 55.967 | 64.232 | 42.062 | 20.992 |
| Operating Income | -87.667 | -78.874 | -87.24 | -60.683 | -27.03 |
| Interest Income (Expense), Net Non-Operating | -2.766 | -2.553 | 0.968 | -0.805 | -0.512 |
| Other, Net | 0.145 | -0.193 | -0.059 | -0.256 | -0.017 |
| Net Income Before Taxes | -90.288 | -81.62 | -86.331 | -61.744 | -27.559 |
| Net Income After Taxes | -90.288 | -81.62 | -86.331 | -61.744 | -27.559 |
| Net Income Before Extra. Items | -90.288 | -81.62 | -86.331 | -61.744 | -27.559 |
| Net Income | -90.288 | -81.62 | -86.331 | -61.744 | -27.559 |
| Income Available to Common Excl. Extra. Items | -90.288 | -81.62 | -86.331 | -61.744 | -27.559 |
| Income Available to Common Incl. Extra. Items | -90.288 | -81.62 | -86.331 | -61.744 | -27.559 |
| Diluted Net Income | -90.288 | -81.62 | -86.331 | -61.744 | -27.559 |
| Diluted Weighted Average Shares | 41.86 | 33.4502 | 25.7033 | 29.3948 | 29.3948 |
| Diluted EPS Excluding Extraordinary Items | -2.1569 | -2.44004 | -3.35876 | -2.10051 | -0.93755 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | |||
| Diluted Normalized EPS | -2.1569 | -2.44004 | -3.33619 | -2.10051 | -0.93755 |
| Unusual Expense (Income) | 0 | 0.58 | |||
| Revenue | 1.104 | 0.975 |
| Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | |
|---|---|---|---|---|---|
| Total revenue | 0.492 | 0.104 | 0.211 | 0.297 | 0.243 |
| Revenue | 0.492 | 0.104 | 0.211 | 0.297 | 0.243 |
| Total Operating Expense | 20.191 | 22.517 | 23.418 | 22.645 | 19.543 |
| Selling/General/Admin. Expenses, Total | 4.617 | 5.106 | 5.785 | 5.46 | 5.205 |
| Research & Development | 15.574 | 17.411 | 17.633 | 17.185 | 14.338 |
| Unusual Expense (Income) | 0 | ||||
| Operating Income | -19.699 | -22.413 | -23.207 | -22.348 | -19.3 |
| Interest Income (Expense), Net Non-Operating | -0.705 | -0.692 | -0.681 | -0.688 | -0.713 |
| Other, Net | 0.132 | 0.02 | -0.001 | -0.006 | -0.003 |
| Net Income Before Taxes | -20.272 | -23.085 | -23.889 | -23.042 | -20.016 |
| Net Income After Taxes | -20.272 | -23.085 | -23.889 | -23.042 | -20.016 |
| Net Income Before Extra. Items | -20.272 | -23.085 | -23.889 | -23.042 | -20.016 |
| Net Income | -20.272 | -23.085 | -23.889 | -23.042 | -20.016 |
| Income Available to Common Excl. Extra. Items | -20.272 | -23.085 | -23.889 | -23.042 | -20.016 |
| Income Available to Common Incl. Extra. Items | -20.272 | -23.085 | -23.889 | -23.042 | -20.016 |
| Diluted Net Income | -20.272 | -23.085 | -23.889 | -23.042 | -20.016 |
| Diluted Weighted Average Shares | 42.5995 | 42.5776 | 42.5386 | 39.6926 | 35.9841 |
| Diluted EPS Excluding Extraordinary Items | -0.47587 | -0.54219 | -0.56158 | -0.58051 | -0.55625 |
| Diluted Normalized EPS | -0.47587 | -0.54219 | -0.56158 | -0.58051 | -0.55625 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 |
- Annual
- Quarterly
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Total Current Assets | 42.311 | 48.721 | 73.279 | 76.243 | 28.551 |
| Cash and Short Term Investments | 38.474 | 46.222 | 71.241 | 76.086 | 28.456 |
| Cash & Equivalents | 38.474 | 46.222 | 71.241 | 76.086 | 28.456 |
| Total Receivables, Net | 0.005 | 0.045 | |||
| Prepaid Expenses | 3.583 | 2.499 | 2.038 | 0.152 | 0.05 |
| Total Assets | 50.137 | 59.344 | 82.306 | 85.325 | 30.747 |
| Property/Plant/Equipment, Total - Net | 5.665 | 8.462 | 6.742 | 4.693 | 1.975 |
| Property/Plant/Equipment, Total - Gross | 11.136 | 11.955 | 9.281 | 5.914 | 2.406 |
| Accumulated Depreciation, Total | -5.471 | -3.493 | -2.539 | -1.221 | -0.431 |
| Other Long Term Assets, Total | 2.161 | 2.161 | 2.285 | 4.389 | 0.221 |
| Total Current Liabilities | 29.682 | 16.659 | 10.377 | 11.301 | 3.854 |
| Accounts Payable | 5.67 | 5.389 | 2.016 | 3.442 | 0.864 |
| Accrued Expenses | 6.686 | 7.356 | 7.086 | 7.406 | 2.615 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 16.144 | 2.634 | 0.068 | 0.091 | 0.104 |
| Other Current Liabilities, Total | 1.182 | 1.28 | 1.207 | 0.362 | 0.271 |
| Total Liabilities | 39.53 | 38.848 | 33.423 | 28.343 | 21.932 |
| Total Long Term Debt | 5.55 | 18.375 | 20.391 | 14.831 | 14.81 |
| Long Term Debt | 5.55 | 18.375 | 20.391 | 14.831 | 14.81 |
| Other Liabilities, Total | 4.298 | 3.814 | 2.655 | 2.211 | 3.268 |
| Total Equity | 10.607 | 20.496 | 48.883 | 56.982 | 8.815 |
| Preferred Stock - Non Redeemable, Net | 153.226 | 52.494 | |||
| Common Stock | 0.043 | 0.036 | 0.03 | 0.006 | 0.005 |
| Additional Paid-In Capital | 375.031 | 294.639 | 241.412 | 9.978 | 0.8 |
| Retained Earnings (Accumulated Deficit) | -364.467 | -274.179 | -192.559 | -106.228 | -44.484 |
| Total Liabilities & Shareholders’ Equity | 50.137 | 59.344 | 82.306 | 85.325 | 30.747 |
| Total Common Shares Outstanding | 42.596 | 36.0228 | 30.1278 | 29.3948 | 29.3948 |
| Redeemable Preferred Stock | 0 | 0 | |||
| Other Current Assets, Total | 0.254 |
| Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | |
|---|---|---|---|---|---|
| Total Current Assets | 42.311 | 58.304 | 74.603 | 95.032 | 48.721 |
| Cash and Short Term Investments | 38.474 | 55.657 | 71.979 | 92.362 | 46.222 |
| Cash & Equivalents | 38.474 | 55.657 | 71.979 | 92.362 | 46.222 |
| Prepaid Expenses | 3.583 | 2.647 | 2.624 | 2.67 | 2.499 |
| Total Assets | 50.137 | 67.804 | 84.29 | 105.026 | 59.344 |
| Property/Plant/Equipment, Total - Net | 5.665 | 7.339 | 7.526 | 7.833 | 8.462 |
| Property/Plant/Equipment, Total - Gross | 11.136 | 12.482 | 12.165 | 11.889 | 11.955 |
| Accumulated Depreciation, Total | -5.471 | -5.143 | -4.639 | -4.056 | -3.493 |
| Other Long Term Assets, Total | 2.161 | 2.161 | 2.161 | 2.161 | 2.161 |
| Total Current Liabilities | 29.682 | 19.261 | 12.269 | 12.873 | 16.659 |
| Accounts Payable | 5.67 | 3.559 | 2.695 | 2.412 | 5.389 |
| Accrued Expenses | 6.686 | 8.681 | 5.014 | 4.403 | 7.356 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 16.144 | 6.384 | 3.667 | 4.759 | 2.634 |
| Other Current Liabilities, Total | 1.182 | 0.637 | 0.893 | 1.299 | 1.28 |
| Total Liabilities | 39.53 | 38.604 | 34.024 | 33.252 | 38.848 |
| Total Long Term Debt | 5.55 | 15.132 | 17.677 | 16.433 | 18.375 |
| Long Term Debt | 5.55 | 15.132 | 17.677 | 16.433 | 18.375 |
| Other Liabilities, Total | 4.298 | 4.211 | 4.078 | 3.946 | 3.814 |
| Total Equity | 10.607 | 29.2 | 50.266 | 71.774 | 20.496 |
| Common Stock | 0.043 | 0.043 | 0.043 | 0.042 | 0.036 |
| Additional Paid-In Capital | 375.031 | 373.352 | 371.333 | 368.953 | 294.639 |
| Retained Earnings (Accumulated Deficit) | -364.467 | -344.195 | -321.11 | -297.221 | -274.179 |
| Total Liabilities & Shareholders’ Equity | 50.137 | 67.804 | 84.29 | 105.026 | 59.344 |
| Total Common Shares Outstanding | 42.596 | 42.5801 | 42.5714 | 42.4832 | 36.0228 |
| Redeemable Preferred Stock | 0 | 0 | |||
| Other Current Assets, Total | 0.254 |
- Annual
- Quarterly
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -90.288 | -81.62 | -86.331 | -61.744 | -27.559 |
| Cash From Operating Activities | -77.094 | -61.518 | -75.796 | -46.316 | -22.495 |
| Cash From Operating Activities | 2.358 | 1.823 | 1.318 | 0.792 | 0.316 |
| Non-Cash Items | 11.099 | 13.728 | 10.433 | 8.14 | 0.738 |
| Cash Interest Paid | 2.133 | 1.925 | 0.881 | 0.943 | 0.343 |
| Changes in Working Capital | -0.263 | 4.551 | -1.216 | 6.496 | 4.01 |
| Cash From Investing Activities | -0.691 | -4.024 | -3.586 | -3.002 | -1.406 |
| Capital Expenditures | -1.129 | -4.024 | -3.586 | -3.002 | -1.406 |
| Cash From Financing Activities | 70.037 | 40.399 | 74.642 | 98.907 | 49.736 |
| Financing Cash Flow Items | -0.359 | -0.079 | -1.158 | -1.84 | 0 |
| Issuance (Retirement) of Stock, Net | 70.396 | 40.546 | 68.391 | 100.852 | 39.86 |
| Issuance (Retirement) of Debt, Net | 0 | -0.068 | 7.409 | -0.105 | 9.876 |
| Net Change in Cash | -7.748 | -25.143 | -4.74 | 49.589 | 25.835 |
| Other Investing Cash Flow Items, Total | 0.438 |
| Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -90.288 | -70.016 | -46.931 | -23.042 | -81.62 |
| Cash From Operating Activities | -77.094 | -59.934 | -44.057 | -23.974 | -61.518 |
| Cash From Operating Activities | 2.358 | 1.754 | 1.16 | 0.577 | 1.823 |
| Non-Cash Items | 11.099 | 9.331 | 7.146 | 4.603 | 13.728 |
| Cash Interest Paid | 2.133 | 1.601 | 1.064 | 0.526 | 1.925 |
| Changes in Working Capital | -0.263 | -1.003 | -5.432 | -6.112 | 4.551 |
| Cash From Investing Activities | -0.691 | -0.693 | -0.262 | -0.03 | -4.024 |
| Capital Expenditures | -1.129 | -0.693 | -0.262 | -0.03 | -4.024 |
| Cash From Financing Activities | 70.037 | 70.062 | 70.076 | 70.144 | 40.399 |
| Financing Cash Flow Items | -0.359 | -0.329 | -0.31 | -0.186 | -0.079 |
| Issuance (Retirement) of Stock, Net | 70.396 | 70.391 | 70.386 | 70.33 | 40.546 |
| Issuance (Retirement) of Debt, Net | 0 | 0 | 0 | -0.068 | |
| Net Change in Cash | -7.748 | 9.435 | 25.757 | 46.14 | -25.143 |
| Other Investing Cash Flow Items, Total | 0.438 |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| Menichella (Daniel L.) | Individual Investor | 0.2996 | 127700 | 107700 | 2022-03-31 | MED |
| Duke (William E. Jr.) | Individual Investor | 0.1598 | 68115 | 68115 | 2022-03-31 | LOW |
| Korn (Jerald) | Individual Investor | 0.1215 | 51803 | 51803 | 2022-03-31 | |
| Melas-Kyriazi (Theo) | Individual Investor | 0.0782 | 33333 | 0 | 2022-03-31 | LOW |
| Quinn (Anthony G) | Individual Investor | 0.0741 | 31603 | 0 | 2022-03-31 | LOW |
| Northern Trust Global Investments | Investment Advisor | 0.0334 | 14235 | 14235 | 2022-12-31 | LOW |
| DWS Investments UK Limited | Investment Advisor | 0.0244 | 10387 | 0 | 2023-02-28 | MED |
| Amalgamated Financial Corp. | Investment Advisor | 0.0077 | 3266 | 3266 | 2022-03-31 | |
| Mackenzie Financial Corporation | Investment Advisor/Hedge Fund | 0.0027 | 1139 | -148 | 2022-09-30 | LOW |
| Westfield Capital Management Company, L.P. | Investment Advisor/Hedge Fund | 0.002 | 854 | 0 | 2021-09-30 | LOW |
| Carroll Financial Associates, Inc. | Investment Advisor | 0.0008 | 339 | 0 | 2021-12-31 |
Why choose Capital.com? Our numbers speak for themselves.
Capital.com Group500K+
Traders
92K+
Active clients monthly
$53M+
Monthly investing volume
$30M+
Withdrawn each month
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Kaleido Biosciences, Inc. Company profile
About Kaleido Biosciences Inc
Kaleido Biosciences, Inc. is a clinical-stage healthcare company focused on leveraging the potential of the microbiome organ to treat disease and improve human health. Its Microbiome Metabolic Therapies (MMTs) is designed to drive the function and distribution of the microbiomes existing microbes in order to decrease or increase the production of metabolites to certain bacteria in the microbiome community. The Company is also advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with unmet patient needs. The Company utilizes its discovery and development platform to study MMTs in microbiome samples to rapidly advance MMT candidates into clinical studies in healthy subjects and patients. Its KB195 is the lead MMT candidate for development in the treatment of patients with urea cycle disorders. The Company is conducting a Phase II clinical trial under an Investigational New Drug Application (IND).
Financial summary
BRIEF: For the nine months ended 30 September 2021, Kaleido Biosciences Inc revenues decreased 16% to $612K. Net loss increased 14% to $70M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - Balancing increase of 33% to $35.1M (expense), Stock-based Compensation in R&D increase of 36% to $3.9M (expense).
| Industry: | Biotechnology & Medical Research (NEC) |
18 Crosby Dr
BEDFORD
MASSACHUSETTS 01730-1402
US
Income Statement
- Annual
- Quarterly
News
China Evergrande offers bond and equity swaps in debt restructuring
Adds proposal detail
15:24, 22 March 2023
Mexico inflation rate brings good news, uncertainty remains -Espinosa
Updates with additional information from interview, context
15:19, 22 March 2023
World refined copper market in 103,000 tonne surplus in January –ICSG
March 22 (Reuters) - The world's refined copper market had a 103,000 tonne surplus in January, compared with a 10,000 tonnes surplus the previous month, the International Copper Study Group (ICSG) said in its latest monthly bulletin.
15:10, 22 March 2023
Fitness chains add financial muscle as more Americans hit the gym
By Deborah Mary Sophia
15:07, 22 March 2023
House Republicans subpoena labor authorities in Starbucks union dispute - WSJ
March 22 (Reuters) - A Congressional committee issued a subpoena to the National Labor Relations Board, alleging that employees of the labor body mishandled union elections at Starbucks Corp SBUX.O cafes in ways that favored unionizing workers, the Wall Street Journal reported on Wednesday, citing a letter.
15:06, 22 March 2023
China Evergrande publishes plan to restructure $22.7 bln offshore debt
HONG KONG, March 22 (Reuters) - China Evergrande Group 3333.HK on Wednesday published long-awaited plans to restructure its $22.7 billion of offshore debt.
15:02, 22 March 2023
Crop merchant Louis Dreyfus to step up spending after earnings boost
Writes through with details, quote
14:59, 22 March 2023People also watch
Still looking for a broker you can trust?
Join the 500.000+ traders worldwide that chose to trade with Capital.com